Clarus Therapeutics Holdings, Inc.
Case Number:
1:22-bk-10845
Court:
Nature of Suit:
Firms
- Benesch
- Bondurant Mixson
- Chiesa Shahinian
- Cross & Simon
- DLA Piper
- Dorsey & Whitney
- Goodwin Procter
- Hogan McDaniel
- Klehr Harrison
- Mayer Brown
- McElroy Deutsch
- Mercer Law LLC
- Miller Nash LLP
- Nixon Peabody
- Pillsbury Winthrop
- Potter Anderson
- Powell Firm
- Saul Ewing
Companies
- Alvarez & Marsal Holdings LLC
- Axtria
- Cardinal Health Inc.
- Cencora Inc.
- Clarus Therapeutics
- Express Scripts Holding Co.
- McKesson Corp.
- Stretto Inc.
- U.S. Bancorp
Sectors & Industries:
-
October 28, 2022
Celsius Network Gets OK To Auction, GWG To Raise Money
Crypto lender Celsius Network got the go-ahead to auction off its assets, bond seller GWG Holdings got permission to raise $630 million to pay back its bankruptcy loans and Axos Bank was hit with an $18.3 million verdict for pilfering MUFG Union Bank's Chapter 7 trustee deposit business. This is the week in bankruptcy.
-
October 26, 2022
Pharma Co. Clarus Gets OK For Ch. 11 Drug Sale
A Delaware bankruptcy judge on Wednesday approved drug company Clarus Therapeutics' sale of its sole product for $7.25 million in cash and tens of millions in potential future royalties and payments.
-
September 07, 2022
Ill. Pharma Co. Gets OK For Fast Sale Of Testosterone Drug
Clarus Therapeutics Inc., a bankrupt manufacturer of a pill that treats low testosterone, received court approval on Wednesday in Delaware bankruptcy court to pay down the interest on its $43 million debt to noteholders and tap into $8.9 million cash on hand to fund the speedy sale of the company's assets.
-
September 06, 2022
Ch. 11 Cheat Sheet: Clarus Therapeutics
Drug company Clarus Therapeutics filed for Chapter 11 protection in Delaware bankruptcy court Monday with plans to auction off its sole asset, a testosterone deficiency treatment, before the end of October.
-
September 06, 2022
Pharma Co. Clarus Hits Ch. 11 With Plan To Sell Sole Drug
Drug company Clarus Therapeutics filed for Chapter 11 protection in Delaware bankruptcy court, saying it is over $54 million in debt and is seeking to auction off its sole asset, a testosterone deficiency treatment.